1-(2-methoxyphenyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one | 141798-75-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(2-methoxyphenyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
• 英文别名: 1-[2-methoxyphenyl]-1H-benzo[d]imidazol-2(3H)-one；1,3-dihydro-1-(2-methoxyphenyl)-2H-benzimidazol-2-one；3-(2-methoxyphenyl)-1H-benzimidazol-2-one
• CAS: 141798-75-6
• 化学式: C₁₄H₁₂N₂O₂
• 分子量: 240.261
• InChiKey: SSILWUSDXOOUDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(2-Iodophenyl)-3-(2-methoxyphenyl)urea 在 copper(l) iodide 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二甲基亚砜 为溶剂， 反应 0.33h， 以93%的产率得到1-(2-methoxyphenyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one
  参考文献：
  名称：

  Copper-Catalyzed Intramolecular Cyclization to N-Substituted 1,3-Dihydrobenzimidazol-2-ones

  摘要：

  An efficient and convenient method was developed for preparing N-substituted 1,3-dihydrobenzimidazol-2-ones from N'-substituted N-(2-halophenyl)ureas via a Cul/DBU-catalyzed cyclization in DMSO under microwave heating. High yields were obtained and a variety of functional groups were tolerated under these conditions, including N'-aryl, alkyl, heterocyclic, various N-(substituted 2-halophenyl) and N-(2-iodopyridyl)ureas.

  DOI：

  10.1021/ol8011106

文献信息

• Chan-Lam cross-coupling reaction based on the Cu 2 S/TMEDA system
  作者：Kateřina Janíková、Lukáš Jedinák、Tereza Volná、Petr Cankař

  DOI：10.1016/j.tet.2017.12.042

  日期：2018.2

  several pinacol or neopentylglycol boronates indicated further potential of the catalyst. The reaction conditions tolerate the hydroxyl and bromo functional groups. The catalytic system also enables to synthesize the mono-N-substituted anilines from primary aliphatic amines. However, the two model compounds for the secondary and aromatic amines, piperidine and aniline, do not react. Two sterically demanding

  基于Chan-Lam交叉偶联反应，开发了一种基于使用稳定铜（I）源的现成Cu 2 S / TMEDA系统的催化剂。用1 H-苯并[ d ]咪唑-2（3 H）-1，1 H-苯并[ d ]咪唑和1 H-咪唑以及缺电子，富电子和在室温下，在大气氧的存在下，对空间需求量高的硼酸，以中等至极好的收率得到交叉偶联的产物。另外，1 H-苯并[ d]的偶联反应]咪唑与几种频哪醇或新戊二醇硼酸酯表明该催化剂的进一步潜力。反应条件容许羟基和溴官能团。该催化体系还能够由伯脂族胺合成单-N-取代的苯胺。但是，仲胺和芳族胺的两种模型化合物哌啶和苯胺不会反应。两个空间要求的产品与受限Ç N键的旋转，通过将合成的Ñ 1的-arylation ħ -苯并[ d ]咪唑-2（3 H ^） -酮与ö-甲苯磺酸，能够确认由Chan-Lam交叉偶联反应制得的阻转异构体。此外，已经报道了一锅Chan-Lam和Suzuki-Miyaura反应的例子。
• Benzimidazole derivatives, their preparation and use
  申请人：NEUROSEARCH A/S

  公开号：EP0477819A2

  公开（公告）日：1992-04-01

  A compound having the formula wherein R1 is hydrogen, NH2 or C1 6-alkyl which may be branched; X is O, S, NCN; Y is O, S; R4, R5, R6 and R7 independently of each other is hydrogen, halogen, CF3, N02, NH2, OH, C1 6-alkoxy, C(=O)-phenyl or S02NR'R" wherein R' and R" independently are hydrogen or C1 6-alkyl; R11 is hydrogen, halogen, N02 or S02NR'R" wherein R' and R" independently are hydrogen or C1 6-alkyl; R13 is hydrogen, halogen, phenyl, CF3, N02; R12 is hydrogen or together with R13 forms a C4 7- carbocyclic ring which may be aromatic or partial saturated; R14 is hydrogen or together with R13 forms a C4 7- carbocyclic ring which may be aromatic or partial saturated; further a method of treating a disease in a mammal, including a human, responsive to opening of potassium channels, which comprises administering to a mammal in need thereof an effective amount of a compound as first above.

  一种化合物，其化学式为 式中 R1 是氢、NH2 或 C1 6-烷基，可为支链； X 是 O、S、NCN Y 是 O、S R4、R5、R6 和 R7 各自是氢、卤素、CF3、N02、NH2、OH、C1 6-烷氧基、C(=O)-苯基或 S02NR'R"，其中 R' 和 R "各自是氢或 C1 6-烷基； R11 是氢、卤素、N02 或 S02NR'R"，其中 R' 和 R "各自是氢或 C1 6-烷基； R13 是氢、卤素、苯基、 、N02； R12 是氢，或与 R13 一起形成一个 C4 7-碳环，该碳环可以是芳香环或部分饱和环； R14 是氢，或与 R13 一起形成 C4 7-碳环，该环可以是芳香的或部分饱和的； 进一步一种治疗哺乳动物(包括人)中对钾通道开放有反应的疾病的方法，该方法包括向需要的哺乳动物施用有效量的上述第一种化合物。
• FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST
  申请人：RaQualia Pharma Inc.

  公开号：US20210078975A1

  公开（公告）日：2021-03-18

  The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR1 and/or CRHR2 is involved.
• US5200422A
  申请人：——

  公开号：US5200422A

  公开（公告）日：1993-04-06
• [EN] BENZIMIDAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTICAL USES THEREOF<br/>[FR] DERIVES DE BENZIMIDAZOLE, LEURS PREPARATIONS ET LEURS APPLICATIONS EN THERAPEUTIQUE
  申请人：SYNTHELABO

  公开号：WO1998004546A1

  公开（公告）日：1998-02-05

  (EN) Compounds of formula (I), wherein A is a nitrogen atom or a CH group; B is a C4-8 cycloalkyl group, a naphthyl group or a group of formula (Y), where n is 0 or 1; X is an oxygen or sulphur atom; Z is a nitrogen atom or a CH group; R2 is a hydrogen atom, a C1-4 alkyl group or a phenyl group; R3 is a C3-6 cycloalkyl group, a phenyl group, benzyl, a furyl group, thienyl, pyrrolyl, pyrazolyl, isoxazolyl, thioazolyl, pyridyl, imidazolyl or benzimidazolyl; and R7 is a hydrogen atom or a straight or branched C1-4 alkyl group; and the therapeutical uses thereof, are disclosed.(FR) Composés de formule (I), dans laquelle A représente un atome d'azote ou un groupe CH, B représente un groupe cyclo C4-8 alkyle, un groupe naphthyle ou un groupe de formule (Y), n représente 0 ou 1, X représente un atome d'oxygène ou de soufre, Z représente un atome d'azote ou un groupe CH, R2 représente un atome d'hydrogène, un groupe C1-4 alkyle, ou un groupe phényle, R3 représente un groupe C3-6 cycloalkyle, un groupe phényle, benzyle, un groupe furyle, thiényle, pyrrolyle, pyrazolyle, isoxazolyle, thiazolyle, pyridyle, imidazolyle ou benzimidazolyle, R7 représente un atome d'hydrogène ou un groupe C1-4 alkyle, linéaire ou ramifié. Application en thérapeutique.